Tevogen (TVGN) Retained Earnings (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Retained Earnings came in at -$145.1 million in Q1 2026, down 17.26% YoY from -$175.4 million in Q1 2025, and down 3.9% on a QoQ basis from -$139.7 million in Q4 2025.
Tevogen (TVGN) Retained Earnings (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Retained Earnings data on file, last reported at -$145.1 million in Q1 2026.
- Quarterly Retained Earnings fell 17.26% year-over-year to -$145.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$145.1 million (down 17.26% YoY) and the FY2025 annual result came in at -$139.7 million, down 242.64% from the prior year.
- Retained Earnings retreated to -$145.1 million in Q1 2026, from -$139.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $111.0 million in Q2 2025 to a low of -$145.1 million in Q1 2026.
- A 5-year average of -$32.9 million and a median of -$15.3 million in 2023 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 1776.82% in 2024, down 543.0% in 2024.
- Tracing TVGN's Retained Earnings over 5 years: stood at -$14.8 million in 2022, then jumped by 135.29% to $5.2 million in 2023, then soared by 1776.82% to $97.9 million in 2024, then sank by 242.64% to -$139.7 million in 2025, then dropped by 3.9% to -$145.1 million in 2026.
- The last three Retained Earnings figures came in at -$145.1 million (Q1 2026), -$139.7 million (Q4 2025), and -$135.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 4.38 Bn |
| 10 | Tevogen | 25.73 Mn | 25.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.11 Mn |
| Dec 31, 2025 | -139.66 Mn |
| Sep 30, 2025 | -134.98 Mn |
| Jun 30, 2025 | 110.95 Mn |
| Mar 31, 2025 | -123.75 Mn |
| Dec 31, 2024 | 97.91 Mn |
| Sep 30, 2024 | -103.94 Mn |
| Jun 30, 2024 | -98.06 Mn |
| Mar 31, 2024 | 76.16 Mn |
| Dec 31, 2023 | 5.22 Mn |
| Sep 30, 2023 | -16.16 Mn |
| Jun 30, 2023 | -15.55 Mn |
| Mar 31, 2023 | -15.33 Mn |
| Dec 31, 2022 | -14.78 Mn |
| Sep 30, 2022 | -14.66 Mn |
| Jun 30, 2022 | -14.05 Mn |
| Mar 31, 2022 | -14.26 Mn |
| Dec 31, 2021 | -14.23 Mn |